내용보기

Full Text:

영남의대학술지 Vol.24_No.2 Suppl. P.S192-202, Dec. 2007

Review

불인성 암성 통증의 비파괴적 수술

Nondestructive Neuroaugmentative Surgery for Intractable Cancer Pain

김성호, 최병연, 조수호

영남대학교 의과대학 신경외과학교실

책임저자：김성호, 대구광역시 남구 대명동 317-1, 영남대학교 의과대학 신경외과학교실

Tel: (053) 620-3790, Fax: (053) 620-3770

E-mail: shkim@medical.yu.ac.kr

December 30, 2007

Abstract

Pain is probably one of the most common cancer symptoms. In addition to being a major source of suffering and disability, cancer pain is extremely frightening for patients and their families. The authors propose to adjust the World Health Organization (WHO) pain management ladder from its current three-step approach to a more sophisticated five-step algorithm that includes physical and psychological modalities along the entire continuum of care and adds two more steps related to neuromodulative and neurodestructive procedures once the opioids fail.
This review discusses the current surgical options for treating cancer pain, focusing on the continuous drug infusion pump currently available and briefly exploring some of the other surgical options for pain management. The introduction of intrathecal opioid administration for intractable cancer pain is considered as one of the most important breakthroughs in pain management. Morphine, the only opioid approved by FDA for intrathecal administration, has been increasingly utilized for this purpose.

Key Words: Intractable cancer pain, Morphine, Continuous drug infusion pump

References

1. Becker R, Jakob D, Uhle EI, Riegel T, Bertalanffy H. The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions. Stereotact Funct Neurosurg 2000;75(1):16-26.

2. Bruera E, Watanabe S, Fainsinger RL, Spachynski K, Suarez-Almazor M, Inturrisi C. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 1995 Aug;62(2):141-6.

3. Gonzales GR, Elliot K. Portenoy RK, Foley KM. The impact of a comprehensive evaluation in the management of cancer pain. Pain 1991 Nov;47(2):141-4.

4. Lordon SP. Interventional approach to cancer pain. Curr Pain Headache Rep 2002 Jun;6(3): 202-6.

5. Yu W, Hao JX, Xu XJ, Saydoff J, Haeger- strand A, Wiesenfeld-Hallin Z. Long-term alleviation of allodynia-like behaviors by intrathecal implantation of bovine chromaffin cells in rats with spinal cord injury. Pain 1998 Feb;74(2-3):115-22.

6. Stein C. The control of pain in peripheral tissues by opioids. N Engl J Med 1995 Jun 22;332(25):1685-90.

7. Mao J. Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interaction. Pain 1995 Sep;62(3):259-74.

8. Brose WG, Tanelian DL, Brodsky JB, Mark JB, Cousins MJ. CSF and blood pharmaco- kinetics of hydromorphine and morphine following lumbar epidural administration. Pain 1991 Apr;45(1):11-5.

9. Elliot K, Hyansky A, Inturissi CE. Dextro- methorphan attenuates and reverses analgesic tolerance to morphine. Pain 1994 Dec;59(3): 361-8.

10. Michalewicz P, Laurito CE, Pappas GD, Lu Y, Yeomans DC. Purification of adrenal chromaffin cells increases antinociceptive efficacy of xenotransplants without immunosuppression. Cell Transplant 1999 Jan; 8(1):103-9.

11. Gourlay GK, Plummer JL, Cherry DA, Onley MM, Parish KA, Wood MM, et al. Comparision of intermittent bolus with continuous infusion of epidural morphine in the treatment of severe cancer pain. Pain 1991 Nov;47(2): 135-40.

12. Bullitt E. Treatment of cancer pain. Contemp Neurosurg 1994;16:15-2.

13. Mollenholt P, Rawal N, Gordh T, Ollson Y. Intrathecal and epidural somatostatin for patients with cancer-analgesic effects and post- mortem neuropathologic investigations of spinal cord and nerve roots. Anesthesiology 1994 Sep;81(3):534-42.

14. Follett KA, Hitchon PW, Piper J, Kumar V, Clamon G, Jones MP. Response of intractable pain to intrathecal morphine: a retrospective study. Pain 1992 Apr;49(1):21-5.

15. Mercadante S. The role of octreotide in palliative care. J Pain Sympt Manage 1994 Aug;9(6):406-11.

16. Uhle EI, Becker R, Gatscher S, Bertalanffy H. Continuous intrathecal clonidine administration for the treatment of neuropathic pain. Stereotact Funct Neurosurg 2000;75(4):167-75.

17. Ready LB, Loper KA, Nessly M, Wild L. Postoperative epidural morphine is safe on surgical wards. Anesthesiology 1991 Sep;75(3): 452-6.

18. Unsicker K. The trophic cocktail made by adrenal chronmaffin cells. Exp. Neurol 1993 Oct;123(2):167-73.

19. Cejas PJ, Martinez M, Karmally S, McKillop M, McKillop J, Plunkett A, et al. Lumbar transplant of neurons genetically modified to secrete brain-derived neurotrophic factor attenuates allodynia and hyperalgesia after sciatic nerve constriction. Pain 2000 May; 86(1-2):195-210.

20. Mercadante S. Intrathecal morphine and bupivacaine in advanced cancer pain patients implanted at home. J Pain Sympt Manage 1994 Apr;9(3):201-7.

21. Wiley RG. Molecular murder. Trens Neurosci 1998 Oct;21(10):423 -26.

22. Krames ES. Intrathecal infusional therapies for intractable pain: Patient management guidelines. J Pain Sympt Manage 1993 Jan;8 (1):36-46.

23. Winne AP, Pappas GD, Das Gupta TK, Wang H, Ortega JD, Sagen J. Alleviation of cancer pain by adrenal medullary transplants in spinal subarachnoid space: a preliminary report. Anesthesiology 1993 Oct;79(4):644-53.

24. Buchser E, Goddard M, Heyd B, Joseph JM, Favre J, de Tribolet N et al. Immunoisolated xenogeneic chromaffin cell therapy for chronic pain: initial experience. Anesthesiology 1995 Nov;85(5):1005-12.

25. Lazorthes Y, Sagen J, Sallerin B, Tkaczuk J, Duplan H, Sol JC, et al. Human chromaffin cell graft into the CSF for cancer pain management: a prospective phase II clinical study. Pain 2000 Jul;87(1):19-32.

26. Shulman M, Joseph NJ, Haller CA. Effect of epidural and subarachnoid injections of a 10% butamben suspension. Reg Anesth 1990 May- Jun; 15(3): 142-6.

27. Hood DD, Eisenach JC, Tuttle R. Phase I safety assessment of intrathecal neostigmine methylsulfate in humans. Anesthesiology 1995 Feb;82(2):331-43.

28. Siegan JB, Hama AT, Sagen J. Suppression of neuropathic pain by a naturally-derived peptide with NMDA antagonist activity. Brain Res 1997 May;755(2):331-4.

29. Beltrutti DP, Moessinger S, Varrassi G. The epidural and intrathecal administration of somatotrophin-release inhibiting factor: native and synthetic analogues.Curr Rev Pain 2000; 4(1):82-90.

30. Kristensen JD, Svensson B, Gordh T Jr. The NMDA-receptor antagonist CPP abolishes nurogenic “wind-up pain” after intrathecal administration in humans. Pain 1992 Nov;51 (2):249-53.

31. Lazorthes Y, Sagen J, Sallerin B, Tkaczuk J, Duplan H, Sol JC, et al. Human chromaffin cell graft into the CSF for cancer pain management. Pain 2000 Jul;87(1):19-32.

32. Wilson SP, Yeomans DC. Genetic therapy for pain management. Curr Rev Pain 2000;4(6): 445-50.

33. Aebischer P, Buchser E, Joseph JM, Favre J, de Thribolet N, Lysaght M, et al. Transplantation in humans of encapsulated xenogeneic cells without immunosuppression. Transplantation 1994 Dec 15;58(11): 1275-7.